Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors
Metrics: PDF 1412 views | HTML 1958 views | ?
Oliver Wood1,*, Jeongmin Woo1,*, Gregory Seumois3,*, Natalia Savelyeva1, Katy J. McCann1, Divya Singh3, Terry Jones2, Lailah Peel1, Michael S. Breen1, Matthew Ward1, Eva Garrido Martin1, Tilman Sanchez-Elsner1,#, Gareth Thomas1,#, Pandurangan Vijayanand1,3,#, Christopher H. Woelk1,#, Emma King1,#, Christian Ottensmeier1,#, for the SPARC Consortium
1Faculty of Medicine, University of Southampton & University Hospital Southampton, Southampton, UK
2Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
3La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA
*These first authors have contributed equally to this work
#These senior authors have contributed equally to this work
Emma King, email: email@example.com
Christopher H. Woelk, email: C.H.Woelk@soton.ac.uk
Keywords: head and neck squamous cell carcinoma, human papilloma virus, tumor-infiltrating lymphocyte, RNA-Sequencing, transcriptome
Received: February 15, 2016 Accepted: June 30, 2016 Published: July 22, 2016
Human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) has a better prognosis than it’s HPV negative (HPV(−)) counterpart. This may be due to the higher numbers of tumor-infiltrating lymphocytes (TILs) in HPV positive (HPV(+)) tumors. RNA-Sequencing (RNA-Seq) was used to evaluate whether the differences in clinical behaviour simply reflect a numerical difference in TILs or whether there is a fundamental behavioural difference between TILs in these two settings. Thirty-nine HNSCC tumors were scored for TIL density by immunohistochemistry. After the removal of 16 TILlow tumors, RNA-Seq analysis was performed on 23 TILhigh/med tumors (HPV(+) n=10 and HPV(−) n=13). Using EdgeR, differentially expressed genes (DEG) were identified. Immune subset analysis was performed using Functional Analysis of Individual RNA-Seq/ Microarray Expression (FAIME) and immune gene RNA transcript count analysis. In total, 1,634 DEGs were identified, with a dominant immune signature observed in HPV(+) tumors. After normalizing the expression profiles to account for differences in B- and T-cell number, 437 significantly DEGs remained. A B-cell associated signature distinguished HPV(+) from HPV(−) tumors, and included the DEGs CD200, GGA2, ADAM28, STAG3, SPIB, VCAM1, BCL2 and ICOSLG; the immune signal relative to T-cells was qualitatively similar between TILs of both tumor cohorts. Our findings were validated and confirmed in two independent cohorts using TCGA data and tumor-infiltrating B-cells from additional HPV(+) HNSCC patients. A B-cell associated signal segregated tumors relative to HPV status. Our data suggests that the role of B-cells in the adaptive immune response to HPV(+) HNSCC requires re-assessment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.